share_log

DEFA14A: Others

DEFA14A: Others

DEFA14A:其他
美股SEC公告 ·  04/22 08:20
Moomoo AI 已提取核心信息
Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A of the Securities Exchange Act of 1934, indicates that the materials are intended to provide further information to shareholders in connection with the company's upcoming decisions. The filing confirms that no additional filing fee is required for these materials. The proxy statement and additional materials are a standard part of the shareholder voting process, allowing Bristol-Myers Squibb's shareholders to be fully informed before casting their votes on corporate matters.
Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A of the Securities Exchange Act of 1934, indicates that the materials are intended to provide further information to shareholders in connection with the company's upcoming decisions. The filing confirms that no additional filing fee is required for these materials. The proxy statement and additional materials are a standard part of the shareholder voting process, allowing Bristol-Myers Squibb's shareholders to be fully informed before casting their votes on corporate matters.
领先的制药公司百时美施贵宝已向美国证券交易委员会(SEC)提交了明确的补充材料,作为其委托书的一部分。该文件是根据1934年《证券交易法》附表14A提交的,表明这些材料旨在向股东提供与公司即将作出的决定有关的更多信息。该文件证实,这些材料不需要额外的申请费。委托书和其他材料是股东投票过程的标准部分,使百时美施贵宝的股东能够在就公司事务进行表决之前充分了解情况。
领先的制药公司百时美施贵宝已向美国证券交易委员会(SEC)提交了明确的补充材料,作为其委托书的一部分。该文件是根据1934年《证券交易法》附表14A提交的,表明这些材料旨在向股东提供与公司即将作出的决定有关的更多信息。该文件证实,这些材料不需要额外的申请费。委托书和其他材料是股东投票过程的标准部分,使百时美施贵宝的股东能够在就公司事务进行表决之前充分了解情况。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息